<?xml version="1.0" encoding="UTF-8"?>
<p>Tipranavir (
 <italic>N</italic>-[3-[(1
 <italic>R</italic>)-1-[(2
 <italic>R</italic>)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3
 <italic>H</italic>-pyran-5-yl]propy l]phenyl]-5-(trifluoromethyl)pyridin-2-sulfonamid) was approved in 2005, and is used as an anti-HIV compound. The drug was shown to be active against FIV 
 <italic>in vitro</italic>.Tipranavir completely prevented FIV replication [
 <xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>,
 <xref rid="B86-vetsci-02-00456" ref-type="bibr">86</xref>]. No studies in FIV-infected cats exist so far, and further studies are needed to investigate the potential of tipranavir in naturally infected cats.
</p>
